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ART ICLE Open Ac ce s s
The POU4F2/Brn-3b transcription factor is
required for the hypertrophic response to
angiotensin II in the heart
Laura Mele1, Lauren J. Maskell1, Daniel J. Stuckey2, James E. Clark3, Richard J. Heads3 and
Vishwanie S. Budhram-Mahadeo1
Abstract
Adult hearts respond to increased workload such as prolonged stress or injury, by undergoing hypertrophic growth.
During this process, the early adaptive responses are important for maintaining cardiac output whereas at later stages,
pathological responses such as cardiomyocyte apoptosis and ﬁbrosis cause adverse remodelling, that can progress to
heart failure. Yet the factors that control transition from adaptive responses to pathological remodelling in the heart
are not well understood. Here we describe the POU4F2/Brn-3b transcription factor (TF) as a novel regulator of adaptive
hypertrophic responses in adult hearts since Brn-3b mRNA and protein are increased in angiotensin-II (AngII) treated
mouse hearts with concomitant hypertrophic changes [increased heart weight:body weight (HW:BW) ratio]. These
effects occur speciﬁcally in cardiomyocytes because Brn-3b expression is increased in AngII-treated primary cultures of
neonatal rat ventricular myocytes (NRVM) or foetal heart-derived H9c2 cells, which undergo characteristic sarcomeric
re-organisation seen in hypertrophic myocytes and express hypertrophic markers, ANP/βMHC. The Brn-3b promoter is
activated by known hypertrophic signalling pathways e.g. p42/p44 mitogen-activated protein kinase (MAPK/ERK1/2) or
calcineurin (via NFAT). Brn-3b target genes, e.g. cyclin D1, GLUT4 and Bax, are increased at different stages following
AngII treatment, supporting distinct roles in cardiac responses to stress. Furthermore, hearts from male Brn-3b KO
mutant mice display contractile dysfunction at baseline but also attenuated hypertrophic responses to AngII
treatment. Hearts from AngII-treated male Brn-3b KO mice develop further contractile dysfunction linked to extensive
ﬁbrosis/remodelling. Moreover, known Brn-3b target genes, e.g. GLUT4, are reduced in AngII-treated Brn-3b KO hearts,
suggesting that Brn-3b and its target genes are important in driving adaptive hypertrophic responses in stressed heart.
Introduction
Terminally differentiated cardiomyocytes in adult hearts
respond to increased workload or chronic haemodynamic
stress by undergoing hypertrophy. During early adaptive
responses, cardiomyocyte undergo characteristic changes
including increased size, cytoskeletal re-organisation and
metabolic switching, which are necessary for maintaining
cardiac output1,2. Under physiological conditions, e.g.
endurance exercise or pregnancy, such hypertrophic
changes can be reversible3. In contrast, sustained patho-
logical stresses, which can be induced by different stres-
sors including neurohumoral activation (e.g. AngII),
volume/pressure overload (e.g. hypertension and aortic
stenosis), or acute cardiac injury (e.g. myocardial infarc-
tion), can drive irreversible, pathological changes such as
cardiomyocyte apoptosis, interstitial ﬁbrosis and adverse
remodelling that precede progression to heart failure4,5.
© The Author(s) 2019
OpenAccessThis article is licensedunder aCreativeCommonsAttribution 4.0 International License,whichpermits use, sharing, adaptation, distribution and reproduction
in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if
changesweremade. The images or other third partymaterial in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to thematerial. If
material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Correspondence: Vishwanie S. Budhram-Mahadeo(v.budhram-mahadeo@ucl.ac.uk)
1Molecular Biology Development and Disease, UCL Institute of Cardiovascular
Science, London, UK
2Centre for Advanced Biomedical Imaging (CABI), Division of Medicine, UCL
Faculty of Medical Sciences, London, UK
Full list of author information is available at the end of the article.
These authors contributed equally: Laura Mele, Lauren J. Maskell
These authors jointly supervised: Richard J. Heads, Vishwanie S. Budhram-
Mahadeo
Edited by A. Peschiaroli
Ofﬁcial journal of the Cell Death Differentiation Association
12
34
56
78
90
()
:,;
12
34
56
78
90
()
:,;
1
2
3
4
5
6
7
8
9
0
()
:,;
12
34
56
78
90
()
:,;
Changes in the hypertrophic heart arise due to altera-
tions in gene expression following the activation of well-
characterised signalling pathways6–11. For example, the
vasoactive peptide, AngII, acts as a Gα(q)-coupled
receptor agonist to activate different kinase pathways e.g.
mitogen-activated protein kinase/extracellular signal-
regulated kinase1/2 (MAPK/ERK); c-Jun N-terminal
kinase or p38 MAPK12,13, which in turn, converge on key
master regulators to control gene expression6–11. Simi-
larly, the calcium-dependent protein phosphatase, calci-
neurin A (CnA), activates the nuclear factor of activated
T-cells (NFAT) transcription factor (TF), which regulates
hypertrophic genes11,13,14.
Gene expression changes can signiﬁcantly affect cardi-
omyocyte fate and function. For example, early hyper-
trophic responses are associated with re-expression of
foetal genes [e.g. atrial natriuretic peptide (ANP),
β-myosin heavy chain (β-MHC)]; cell cycle regulators (e.g.
cyclin D)15–17; activation of oncogenes (e.g. c-myc and c-
fos)18,19 and increased insulin-responsive glucose trans-
porter GLUT420. On the other hand, chronic stress or
injury, which induces pro-apoptotic genes such as p53
and Bax, will drive irreversible cardiomyocyte apoptosis,
interstitial ﬁbrosis and heart failure21–25.
Therefore, gene expression must be tightly regulated at
multiple levels and central to this process is gene tran-
scription by the RNA polymerase II (RNAPII) enzyme.
RNAPII-mediated gene transcription depends upon
DNA-binding TFs, which promote the assembly of the
transcriptional complex and rate of transcription26.
Tissue-speciﬁc TF, which are expressed in speciﬁc cells or
under different conditions, often control multiple target
genes and therefore act as master regulators that deter-
mine cell fate. In the heart, TFs such as GATA4, MEF2
and NKX2.5 are implicated in transcription of cardiac
genes under different conditions11,27,28. We are studying
the POU4F2/Brn-3b TF, (called Brn-3b), which was ori-
ginally isolated from neuronal cells but has since been
identiﬁed in many other tissues including the heart29–31.
Brn-3b is a member of the POU (Pit-1/Oct-1/Unc-86)
homeodomain TF family, characterised by a highly con-
served POU DNA binding domain. The gene encoding
Brn-3b, consists of two exons separated by an intron,
which can give rise to two distinct isoforms of Brn-3b, via
alternative promoter usage. The longer Brn-3b(l) isoform
is encoded by both exons 1 and 2, whereas the shorter
Brn-3b(s), is encoded by exon 2 only. At present, the roles
of different Brn-3b isoforms are unclear, but an auto-
regulatory feedback loop links expression of the different
isoforms29.
Importantly, Brn-3b controls transcription of multiple
target genes, but its effects are highly dependent on the
tissue of expression and growth conditions29–31. For
example, Brn-3b is essential for survival and function of
retinal ganglion cells (RGCs) in the eye because con-
stitutive Brn-3b knockout (KO) mice develop progressive
blindness due to loss of RGCs. In these cells, Brn-3b target
genes include Pax4 and sonic hedgehog32,33. However,
Brn-3b promotes cell proliferation/growth in other cells
by activating cell cycle genes, cyclin D1/CDK434–37 but
can confer drug resistance and migratory potential to
cancer cells by activating the small heat shock protein,
HSP27 and/or repressing adhesion molecule plakoglobin
(γ-catenin)38,39. Yet, if Brn-3b is co-expressed with the
growth inhibitory p53 protein, then it cooperates with p53
to maximally increase transcription of pro-apoptotic
genes such as Bax, thereby increasing apoptosis40–42.
Therefore, to understand its mechanism of action, it is
important to identify tissue-speciﬁc effects of Brn-3b.
Brn-3b is highly expressed in foetal hearts with
expression detected in cardiomyocytes in heart sections
and primary isolated cultures of cardiomyocytes43.
Although expressed at lower levels in adult hearts42, Brn-
3b is increased throughout the myocardium by 24 h after
coronary artery ligation40. Around the infarct zone, Brn-
3b co-expression with p53 causes increases Bax protein
linked to cardiomyocyte apoptosis. Brn-3b is required for
maximal Bax induction when co-expressed with p53 in
injured cardiomyocytes because reducing Brn-3b in pri-
mary neonatal rat ventricular cardiomyocytes (NRVM)
cultures, using short interfering RNA (shRNA) blocks Bax
expression, even when p53 expression is intact40,42.
However, the effects of Brn-3b in non-injured myo-
cardium, lacking p53 is still unknown and must be
investigated.
In this study, we demonstrate that known hypertrophic
mediators, AngII and CnA, increase Brn-3b in intact
mouse hearts, primary NRVM cultures and H9C2 cells.
Differential regulation of known Brn-3b target genes fol-
lowing AngII treatment indicate potential roles in con-
trolling cell fate. In vivo studies identiﬁed baseline
differences in contractile efﬁciency in male Brn-3b KO
hearts while attenuated hypertrophic response to AngII in
male hearts, is linked to extensive ﬁbrosis and adverse re-
modelling, suggesting that mutant hearts are unable to
adapt to stress.
Materials and methods
Materials
General laboratory reagents: Merck (Nottingham, UK)
and Sigma (Dorset, UK), unless otherwise stated. Primary
antibodies: Brn-3b-rabbit pAb (Abcam-Cambridge, UK);
mouse β-MHC Ab (Gene Tex, CA, USA); α-actinin mAb
(Sigma, UK): GLUT4 (Cell Signalling Technology, USA),
GAPDH and cyclin D1 Ab (Santa Cruz, California, USA)
and β-tubulin (Cell Signalling Technology, USA), p53
pAb (Calbiochem); anti-rabbit Bax pAb (Pharmingen);
rabbit anti-phospho-SMAD 3 pAb (Millipore). (HRP-
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conjugated secondary Ab was from Dako (Cambridge-
shire, UK). MEK inhibitor, PD98059, p38 kinase inhibitor:
SB203580, CnA inhibitors: cyclosporine A (CsA) and
ascomicin were from Calbiochem (Nottingham, UK).
H9c2 cell line was obtained from ATCC (Manassas, VA,
USA) and hearts from calcineurin Aα transgenic mice
were a kind gift from Prof. J Molkentin (Children’s Hos-
pital Medical Center, Cincinnati Ohio, USA). Primer
Sequence for RT-PCR:
ACTB: F-5′GGCTGTATTCCCCTCCATCG 3′; ACTB
R- 5′CCAGTTGGTAACAATGCCATGT 3′
ANF: F-5′ TGGGCTCCTTCTCCATCACC 3′; ANF R -
5′ GCCAAAAGGCCAGGAAGAGG 3′
β-MHC F-5′GCCTACCTCATGGGACTGAA 3′;
β-MHC R - 5′ ACATTCTGCCCTTTGGTGAC 3′
Brn-3b F-5′ GAGAGAGCGCTCACAATTCC 3′; Brn-
3b R- 5’ ATGGTGGTGGTGGCTCTTAC 3′
Bax F-5′ CTGCAGAGGATGATTGCTGA 3′; Bax R 5′
GATCAGCTCGGGCACTTTAG 3′
B2M F-5′ GGTCTTTCTGGTGCTTGTCTCA 3′; B2M
R 5′ GTTCGGCTTCCCATTCTCC 3′
GAPDH F-5′ CTTCATTGACCTCAACTAC 3′;
GAPDH R 5′ AGTGATGGCATGGACTGTG 3′
Methods
In vivo AngII treatment and echocardiography
All animal experiments were carried out in compliance
with Home Ofﬁce regulations (Animals Scientiﬁc Proce-
dures Act 1986) and were approved by local UCL Ethics
Review Board. Early studies were undertaken using wild-
type (WT) C57Bl/6 mice purchased from commercial
companies (Harlan, UK) and at later stages, using KO
mice and age/sex matched WT littermate controls
obtained by crossing inbred Brn-3b heterozygotes. For
early studies, 2-month-old mice (purchased from Harlan
UK) were anaesthetised [1.5% isoﬂurane v/v in 100% O2
with analgesia (buprenorphine 0.1 mg kg−1 SC)] and
subcutaneous implantation of Alzet osmotic mini pumps
(at the nape of the neck) used to administer AngII
(4.5 mg/kg/day) for up to 4 weeks. Saline was given to age-
matched control groups.
To assess for changes in cardiac function and heart
dimensions in Brn-3b KO mutants and age-matched WT
controls, echocardiography was undertaken in anaes-
thetised mice on a weekly basis, using high frequency
(30MHz) ultrasound system (Visualsonics Vevo 2100,
Toronto, CA, USA)44. At the end of studies, measurement
of the heart weight and body weight (HW:BW) ratio was
combined with parameters such as left ventricular (LV)
mass and septal thickness to determine hypertrophic
changes45. Since the study was intended to analyse gene
expression and effects speciﬁcally in hypertrophic hearts,
then key hypertrophic endpoints, e.g. increased LV mass
or HW:BW ratio, were used to identify outliers, i.e. WT
mice that showed no hypertrophic responses to AngII
treatment possibly because of blockages in the mini
osmotic pump.
At the end of experiments, isolated hearts were either
snap-frozen for RNA or protein extraction or ﬁxed in 4%
PFA and subsequently parafﬁn embedded for sectioning.
Statistical analysis was carried out using Students’ t test to
identify signiﬁcant changes (*p < 0.05) between two
groups whilst two-way ANOVA and Bonferroni post-hoc
test were carried out to identify differences within mul-
tiple groups.
Pressure–volume measurements
Assessment of pressure–volume relationship in mouse
hearts were achieved using the Admittance-derived PV
loop system (ADVantageTM; Scisense Inc.), as previously
described45,46. Brieﬂy, mice were anaesthetised with iso-
ﬂurane by passive inhalation then intubated for continued
administration of anaesthetic (1.5% v/w) in 100% oxygen
using a ventilator (Hugo Sachs electronic MiniVent type
845, Germany). Body temperature was monitored using a
rectal thermometer and maintained around ~37 °C,
throughout the experiment by using a thermostatically
controlled heating pad. An ultra-miniature conductance
catheter (Scisense Inc., London, Canada) was inserted into
the left ventricle via the apex, as previously described46
and connected to the ADVantage™ system for generation
of PV loops, which were recorded using the PowerLab
multi-channel acquisition system (Powerlab, ADInstru-
ments, UK). PV loops were acquired at baseline followed
by altered preload, achieved using transient (4–5 s)
occlusion of the inferior vena cava. Data collected using
PowerLab software were analysed for signiﬁcant changes
using appropriate statistical packages e.g. Excel or Prism.
Statistical signiﬁcance, indicated by * or **, was deter-
mined by student’s t test and deﬁned as p < 0.05 or <0.01
respectively.
Primary cultures
Primary NRVM cultures were prepared from hearts of
1–2-day-old Sprague Dawley rats as previously descri-
bed40. Brieﬂy, isolated neonatal hearts were washed in ice-
cold ADS buffer (116 mM NaCl, 20 mM HEPES, 0.8 mM
NaH2PO4, 5.6 mM glucose, 5.4 mM KCl, and 0.6 mM
MgSO4) pH 7.35, cut into pieces and digested with Type 2
collagenase (0.5 mg/ml) (Worthington Biochemical Corp,
NJ) and pancreatin (0.6 mg/ml) (Sigma). The cells were
pelleted by centrifugation then resuspended in Dulbecco’s
Modiﬁed Eagle’s Medium (DMEM): Medium 199 (4:1)
containing 10% horse serum and 5% foetal calf serum
(FCS) (Gibco, Invitrogen Corporation, Auckland, NZ).
Following pre-plating for 1h to remove ﬁbroblasts, cells
were plated on gelatine-coated six-well plates (2 × 106
cells/well). After 24 h, media were replaced with 4:1
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DMEM/Medium 199 supplemented +1% FCS and incu-
bated for 48 h before experiments. Cells were treated with
AngII (at ﬁnal concentrations of 10 µg/ml or 30 µg/ml)
and incubated for the times indicated.
Cell culture, transfection and luciferase assay
H9c2 cells, grown in DMEM+ 10% FCS+ 1% pen/
strep, were plated onto six-well plates (5 × 105/well) and
treated as speciﬁed e.g. AngII (10 µg/ml); PD98059 (10-
20 µm); CsA (1 µm). Ascomicin (1 µm) pretreatment
was for 30 min prior to adding AngII for 24 h. For
transfection studies, GeneJuiceTM (Merck Biosciences,
Nottingham, UK) was used according to the manu-
facturer’s protocol co-transfected the Brn-3b reporter
construct (Brn-3b promoter driving expression of the
luciferase reporter) and expression vector encoding
CnA. Unless otherwise speciﬁed, cells were harvested
after 48 h into lysis buffer and the extracts were used to
analyse for changes in promoter activity. Brieﬂy,
20–50 µL of extract was used to measure luciferase
activity using the TD 20/20 luminometer (Turner
Designs, Promega, Southampton, UK) and the Dual-
Luciferase Reporter Assay System (Promega, South-
ampton, UK), according to the manufacturer’s protocol.
Values for ﬁreﬂy luciferase reporter activity were
adjusted using renilla luciferase controls to correct for
transfection efﬁciency then expressed as percentage of
vector control. Statistical analyses were carried out
using students t -test and signiﬁcance *p < 0.05.
RNA extraction, cDNA synthesis and quantitative
polymerase chain reaction (qRT-PCR)
RNA was isolated from snap-frozen, homogenised
hearts using TRIZOL® Reagent (Invitrogen), whereas
NRVM or H9c2 cells were harvested in Trizol then pro-
cessed according to the manufacturer’s protocol. Con-
taminating genomic DNA was removed from RNA by
treatment with RNAse-free DNAse1 (Promega, South-
ampton, UK) and 1 μg of total RNA was used for cDNA
synthesis (Superscript™ II Reverse Transcriptase (Invitro-
gen)). Quantitative reverse transcriptase (RT) polymerase
chain reaction (qRT-PCR) was carried out using the
Opticon 2 DNA engine thermal cycler (BioRad) and
Taqman probes (ABI) or SYBR Green chemistry with
speciﬁc primers for each gene. Housekeeping genes, beta-
2 microglobulin (B2M) and GAPDH were used to correct
for variability between samples. Statistical analysis was
carried out using student’s t test. Signiﬁcance is shown as
*p < 0.05.
Protein preparation and quantiﬁcation
Cells were harvested in Laemmli buffer; mouse hearts
were homogenised in liquid nitrogen then resuspended
in Laemmli buffer +10% (v/v) β-mercaptoethanol;
boiled (100 °C, 5 min) and centrifuged (13 × g, 10 min
RT) to remove cellular debris. Total cellular proteins
were resolved by polyacrylamide gel electrophoresis
(10–12.5% gels) and western blot analysis carried out as
previously described40. Brieﬂy, block buffer [phosphate-
buffered saline+ 0.1% Tween-20 (PBS-T); 4% milk] was
incubated for 1 h; primary Ab was incubated for 1 h (RT)
or overnight (4 °C). After ﬁve washes (5 min; RT; PBS-T
+ 0.1% milk) secondary Ab was incubated for 1 h then
washed (4 × 5 min; RT; PBS-T + 0.1% milk and ﬁnal 1 ×
5 min wash in PBS-T), signals were developed using
enhanced chemiluminescence reagent (Bio Rad, UK).
Immunoblots were analysed using densitometry or
image J.
Co-immunostaining for protein localisation
Cultured cells grown on coverslips were either treated
with AngII or left untreated (control) (as speciﬁed) then
ﬁxed (4% PFA; 15 min), washed in 1× TBS and incu-
bated in block solution [20% goat serum in TBS +0.1%
triton-X100 (TBST)] for 60 min. Primary antibodies
[rabbit Brn-3b pAb (Abcam-1:500) and α-actinin mAb
(Sigma, UK)] were incubated for 1 h at RT or overnight
at 4 °C. If sequential co-immunostaining was carried
out, the second primary antibody was incubated after
washing cells (×5 with TBST; 1 h; RT). Second Ab (was
appropriate ﬂuorescent conjugated) was incubated for
45 min to 1 h, RT and following washes, cells mounted
in mounting medium containing DAPI (Vector
Laboratories) and imaged using the Zeiss Axioscop 2
ﬂuorescent microscope and analysed with Axiovision
software or Image J.
Chromatin Immunoprecipitation (ChIP) assay
This technique was carried out as described by Lee et al.
and Ounzain et al.38,47 using rat heart-derived H9C2 cells
treated with 10 µg/ml AngII for 24 h or untreated for
control. Anti-NFAT Ab (BioLegend) was used to immu-
neprecipitate NFAT proteins bound to the Brn-3b pro-
moter, whereas anti-β-tubulin or 2nd Ab (Dako) was used
for negative control ChIP samples. The positive control
DNA, Input, was removed from the samples after soni-
cation but prior to immunoprecipitation with Abs. Input
or ChIP DNA were used for PCR with multiple primer
sets that ﬂanked putative NFAT sites in the Brn-3b pro-
moter, and bands shown were obtained following PCR
using the following primer set to amplify ChIP DNA or
positive/negative control DNA. Forward primer 5′
GAAGTGAAAC TCTGACTTGAC 3′; Reverse primer 5′
CAGCTCTGAGATATTTTTAGTG 3′. PCR products
were resolved by gel electrophoresis (2% agarose TBE gel)
and imaged using a CCD camera.
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Immunohistochemistry of parafﬁn-embedded heart
sections
Heart sections were dewaxed and rehydrated before
antigen retrieval [microwave for 10min in 0.01M sodium
citrate (pH 6.0)] and incubation with 0.3% hydrogen
peroxide (30 min, RT). Sections were incubated with the
blocking solution i.e PBST [(phosphate-buffered saline +
0.1% Tween 20) +(10% goat serum)] for 30 min, RT fol-
lowed by incubation with primary antibody [e.g. rabbit
anti-phospho-SMAD 3 pAb° (Millipore, 1:50)] in a
humidiﬁed chamber; overnight at 4 °C. Negative second-
ary Ab° control was included in each experiment. After
washes (5 × 5 min) with PBST, slides were incubated for
1 h (RT) with the biotinylated anti-rabbit secondary (Cell
Signalling 1:200), and colorimetric detection was carried
out using DAB substrate (Sigma), according to the man-
ufacturer’s protocol. After immunostaining, slides were
dehydrated in graded ethanol series, washed twice in
Xylene before mounting. Slides were imaged using the
Hamamatsu Nanozoomer whole-slide imaging function
and analysed using the NDP view 2 software (Hamamatsu,
Japan).
Masson’s trichrome staining
This technique was used to analyse for changes in car-
diac morphology and assess ﬁbrosis (ECM deposition).
Formalin ﬁxed, parafﬁn embedded heart sections from
Brn-3b KO and WT mice were dewaxed, rehydrated then
stained with Masson’s trichrome, using the SAKURA
Tissue Tek DRS 2000 automatic slide stainer (Sakura
Finetek Europe, Netherlands). Slides were cover slipped
on an automated Glass Coverslipper (e.g. Leica CV5030),
imaged using Hamamatsu Nanozoom whole-slide ima-
ging function and analysed using the NDP view 2 software
(Hamamatsu, Japan).
Assessment of cardiomyocyte size using wheat germ
agglutinin (WGA) staining
WGA staining was used to assess changes in the car-
diomyocyte size in WT and Brn-3b KO hearts following
AngII treatment when compared with saline control
hearts. Following dewaxing and rehydration, heart sec-
tions were incubated with 5 µg/ml WGA 488A conjugate
(Biotium) in HBSS in the dark (30 min at RT). Unbound
WGA was washed with HBSS (×1) and PBS (×2) and
sections were mounted using mounting medium con-
taining DAPI. Slides were imaged using AxioScan.Z1 and
cell area was analysed using ImageJ software with >30
cells measured for each heart section.
TUNEL staining
To evaluate cell death in heart sections, TUNEL stain-
ing was undertaken using the DeadEnd Colorimetric
TUNEL System (Promega, Southampton, UK) according
to the manufacturer’s protocol. Sections were imaged
using Hamamatsu Nanozoomer whole-slide imaging
function and analysed using the NDP view 2 software
(Hamamatsu, Japan).
Results
AngII stimulates Brn-3b expression in hypertrophic
cardiomyocytes
Since Brn-3b re-expression in injured adult hearts affects
gene expression and cell fate40, we tested if this TF is
increased in response to stimuli that induce hypertrophic
responses in the heart. Therefore, Brn-3b levels were ana-
lysed in WT mouse hearts following treatment with AngII
for up to 4 weeks and compared with saline infused control
(Con) mouse hearts. Figure 1a shows that AngII treatment
caused the expected hypertrophic changes including
increased HW:BW ratio, LV mass and septal thickness
compared with saline control hearts. AngII-treated hearts
also expressed increased Brn-3b mRNA (Fig. 1b) whereas
western blot analysis conﬁrmed that similar increases in
Brn-3b protein, correlated with induction of hypertrophic
marker β-MHC (Fig. 1c). Increased immunostaining of Brn-
3b in sections of AngII-treated hearts also conﬁrmed its
activation by AngII (Fig. 1d).
We next tested if AngII treatment affected Brn-3b levels
in isolated cardiomyocytes by analysing its expression in
primary NRVM cultures, treated with 10 or 30 µg/ml of
AngII, for 24 h. Figure 2a(i) shows that 10 or 30 µg /ml
AngII caused similar increases in Brn-3b mRNA, which
correlated with induction of hypertrophic markers, ANP
and βMHC. Western blot analysis showed increased
protein in AngII-treated cells, particularly Brn-3b(s) iso-
form (Fig. 2a(ii)). Time-course studies demonstrated that
treatment with 10 µg/ml AngII, which induced hyper-
trophic markers ANP and β-MHC, also increased Brn-3b
mRNA after 8 or 24 h (Fig. 2b). Therefore, subsequent
experiments were carried out using 10 µg/ml AngII
treatment for 24 h.
Co-immunoﬂuorescence staining was undertaken using
Brn-3b and α-actinin antibodies to study Brn-3b locali-
sation and cytoskeletal changes in AngII-treated or
untreated NRVM cultures. Representative images (Fig. 2c)
show nuclear localisation of Brn-3b in AngII-treated
NRVM, which display characteristic cytoskeletal re-
organisation of hypertrophic responses when compared
with control cells.
Similar studies were conducted in the embryonic rat
heart-derived H9c2 cells, which express Brn-3b40 and
undergo characteristic hypertrophic changes in response
to AngII treatment48. Figure 3a, b shows that AngII
induced comparable increases in Brn-3b mRNA and
protein levels while immunostaining conﬁrmed nuclear
localisation in AngII-treated cells (Fig. 3c). Since AngII
induces Brn-3b in both NRVM and H9c2 cells, these
Mele et al. Cell Death and Disease          (2019) 10:621 Page 5 of 18
Ofﬁcial journal of the Cell Death Differentiation Association
results support H9c2 cell line as an appropriate model for
in-depth studies to understand Brn-3b effects/role(s) in
mediating hypertrophic responses.
Brn-3b promoter is activated by known hypertrophic
signalling pathways
AngII-mediated hypertrophic responses in the heart can
be elicited by activation of different signalling pathways
including p42/44MAPK/ERK, which was shown to acti-
vate the Brn-3b promoter in cancer cells47. Therefore, we
next tested if this pathway also activated the Brn-3b
promoter in response to AngII treatment. For this, H9c2
cells were transfected with a Brn-3b reporter construct, in
which the Brn-3b promoter drives expression of the ﬁreﬂy
luciferase reporter gene. After 24 h, transfected cells were
treated with MEK1/2 inhibitor, PD98059 or selective p38
inhibitor, SB203580, while controls were left untreated.
Following AngII treatment for another 24 h, reporter
assays were undertaken. Figure 4a shows that PD98059
repressed basal promoter activity, whereas the SB203580
had no effect on basal promoter activity. As expected,
AngII treatment activated the Brn-3b promoter and its
effects were blocked by treatment with PD98059 but not
SB203580, indicating that AngII activation of Brn-3b was
mediated via p42/44MAPK/ERK1 pathway.
We next tested if CnA also activated Brn-3b promoter
by co-transfecting the Brn-3b reporter construct with
constitutively active CnA expression vector. After 24 h,
transfected cells were treated with a CnA inhibitor, CsA
for 24 or left untreated (control). Reporter assays showed
that CnA activated the Brn-3b promoter when compared
with vector control (Fig. 4b). CsA did not affect basal
promoter activity but blocked induction by CnA, sug-
gesting direct activation of the Brn-3b promoter by CnA.
AngII treatment of CnA-transfected cells did not increase
Brn-3b promoter activity further but treatment with CsA
prevented AngII-mediated promoter activation. Combi-
nations of CsA and PD98059 had no further effect on
Fig. 1 Altered Brn-3b expression mRNA in mouse hearts treated with AngII. a Assessment of hypertrophic responses in hearts taken from AngII-
treated wild-type C57BL/6 mice and compared with saline-treated control mouse hearts. Measurements of heart weight:body weight ratio (HW:BW);
LV mass and septal thickness is shown as mean and standard error from different experimental groups (n= 6). b Results of quantitative RT-PCR (qRT-
PCR) showing increased Brn-3b mRNA in hearts taken from AngII-treated mice compared with saline controls. Statistical signiﬁcance between groups
(≥5 mice) (**p < 0.01) was analysed using students t test. c Representative western blot showing increased (i) Brn-3b or (ii) beta MHC proteins in
mouse hearts either treated with AngII for up to 4 weeks, compared with saline control (Con). d Representative DAB immunostaining showing
increased Brn-3b protein expression in AngII-treated mouse hearts. Images were taken using the Hamamatsu Nanozoomer scanner and shown at
×20 and ×40, as indicated
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Fig. 2 Brn-3b induction by AngII in neonatal rat ventricular myocytes (NRVM) cultures. (a) (i) qRT-PCR data showing changes in mRNA
encoding Brn-3b or hypertrophic markers ANF and β-MHC in NRVM treated with different concentrations (10 or 30 µg/ml) of AngII for 24 h, when
compared with untreated control cells (Con). Variations in RNA from different samples were standardised using the housekeeping gene, β2-micro-
globulin (B2M) mRNA expression and values were expressed relative to untreated control cells set at 1. Graphs represent the mean values ± SD from
independent NRVM samples (n= 6). *p < 0.05. (ii) Representative western blot analysis showing induction of Brn-3b proteins following treatment
with 10 µg/ml AngII for 24 h. Different Brn-3b isoforms (~43 and ~32 kDa) are indicated and the invariant GAPDH protein indicated any variation in
protein loading. (b) Quantiﬁcation of mRNA encoding Brn-3b or hypertrophic markers, ANP and β-MHC in NRVM cultures treated with 10/ml AngII for
different times (4, 8, 24 h). Variations in mRNA between samples were standardised using B2M and values expressed relative to untreated control cells
set at 1. Graphs represent the mean values ± SD from six independent experiments (n= 6). **p < 0.01 compared with untreated controls (Con). (c)
Representative immunoﬂuorescent images showing localisation of Brn-3b protein (Alexa Fluor 488–green) in AngII-treated NRVM co-stained with
phalloidin (red) to demonstrate actin cytoskeleton reorganisation and DAPI staining (blue) showing cell nuclei. Images shown were taken at ×100
magniﬁcation (oil immersion lens) using the Zeiss Axioskop 2 microscope
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promoter activity. This data suggests crosstalk between
CnA and MAPK/ERK pathways in activating the Brn-3b
promoter in hypertrophic cells, with potential con-
vergence of these pathways downstream of ATR1 activa-
tion49. This was conﬁrmed in separate studies showing
that the FK506 analogue, ascomicin, which is another
CnA inhibitor, also reduced Brn-3b protein expression in
AngII-treated H9c2 cells (Fig. 4c).
Since CnA normally mediates its effects by activating
NFAT TFs14, bioinformatic analysis was done on the 6 kb
Fig. 3 Brn-3b induction by AngII in H9c2 cell cultures. a qRT-PCR data showing changes in mRNA encoding Brn-3b, ANP and β-MHC in H9c2 cells
treated with 10 µg/ml of AngII for 4, 8 or 2 h when compared with untreated controls (Con). Variation between RNA samples was standardised using
B2M, and values are expressed relative to the untreated control cells set at 1. Data represent values from six independent experiments and **p < 0.01,
where (n= 6). b Representative western blot analysis showing induction of Brn-3b(s) protein following treatment with 10 µg/ml AngII for 24 h and
the invariant GAPDH protein indicates any variability in protein loading. c Representative immunoﬂuorescent images showing Brn-3b protein
localisation (green) in AngII-treated H9c2 cells stained with phalloidin (red) to show cytoskeletal re-modelling. DAPI staining (blue) shows the cell
nuclei. Untreated control cells are shown at ×40 to demonstrate little protein expression in a larger ﬁeld of view, whereas ×100 magniﬁcation of
AngII-treated cells highlights nuclear Brn-3b expression in cells that display extensive cytoskeletal remodelling
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Fig. 4 (See legend on next page.)
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proximal Brn-3b regulatory promoter sequence. This
approach identiﬁed multiple NFAT-binding sites
throughout the Brn-3b promoter (Fig. 4c). Therefore,
ChIP assays were performed to test for NFAT binding to
the Brn-3b promoter, in vivo, in untreated or AngII-
treated H9c2 cells. ChIP DNA obtained using NFAT
antibody, positive control (input DNA) or negative con-
trol (unrelated Ab) was used for PCR with primers
designed to ﬂank NFAT sites, across the promoter. Figure
4e shows the PCR products (~180 bp) obtained following
ampliﬁcation with the primers shown in Fig. 4c, using
input DNA (positive control) or ChIP DNA immuno-
precipitated from AngII-treated cells with NFAT Ab but
not in untreated cells or Ab control. These results conﬁrm
that NFAT indeed binds to the Brn-3b promoter in
hypertrophic cells while enhanced binding following
AngII treatment supports activation of CnA/NFAT by
AngII and a direct role in regulating Brn-3b expression.
To determine if overexpression of CnA increased
endogenous Brn-3b, in vivo, protein levels were quantiﬁed
in hearts taken from CnA transgenic mice (CnA-TG) with
cardiomyocyte speciﬁc overexpression of CnA. Figure 4f(i,
ii) shows that CnA-TG hearts expressed higher endo-
genous Brn-3b(s) protein, when compared with non-
transgenic hearts indicating that high CnA expression
induces Brn-3b in the heart.
Known Brn-3b target genes that affect cell fate are
increased in response to AngII
Known Brn-3b target genes, cyclin D1, GLUT4 and Bax
are implicated in hypertrophic responses17,50–52 so we
analysed for changes in expression of these genes in
AngII-treated hearts that express the hypertrophic mar-
ker, βMHC and high Brn-3b (Fig. 5a(i, ii)). Representative
western blots show that increased Brn-3b correlated with
higher levels of cyclin D1 and GLUT4 (Fig. 5a(i)) and Bax
(iii). p53 protein was also increased in AngII-treated
hearts (Fig. 5a(iii)) so may cooperate with Brn-3b to
maximally induced Bax.
Similar studies carried out in AngII-treated NRVM
cultures show that increased Brn-3b in AngII-treated cells
was associated with induction of GLUT4 and cyclin D1
(Fig. 5b(i)), when compared with untreated cells. Low
levels of Bax in untreated cells suggest basal stress
responses in the primary NRVM cultures but this was
signiﬁcantly increased following AngII treatment
(Fig. 5b(ii)).
More detailed time course analyses were performed in
H9C2 cells and the data shows that Brn-3b was increased,
as early as 2 h after treatment, with progressive increases
at later times and this correlated with induction of β
−MHC (Fig. 5c). Brn-3b target genes GLUT4 and cyclin
D1 were also increased by 2 h after AngII treatment, with
maximal expression at 8 h. In contrast, pro-apoptotic Bax
was undetectable at early stages but was induced at later
stages, with maximal expression seen at 24 h (Fig. 5c (ii)).
Since p53 expression did not change signiﬁcantly fol-
lowing AngII treatment in these cells, maximal Bax
induction at 24 hours seem to depend on co-expression of
both Brn-3b and p53, as previously shown40. These results
indicate that AngII induction of Brn-3b can trigger time-
dependent, differential regulation of distinct target genes
in cardiomyocytes and its effects will be affected by co-
expression with other regulators such as p53.
(see ﬁgure on previous page)
Fig. 4 Signalling pathways involved in AngII activation of Brn-3b. a Results of reporter assays carried out using extracts from H9c2 cells
transfected with Brn-3b promoter either alone (Con) or following treatment as speciﬁed i.e. angiotensin II (AngII) (10 µg/ml) ±MEK1/2 inhibitor (PD) at
20 µM (or ±p38 MAPK inhibitor (SB) at 5 µM. Promoter activity was expressed as % untreated control cells (transfected with reporter construct or
empty expression vector), set arbitrarily at 100%. Data from six independent samples are shown and statistical signiﬁcance (*p < 0.05 increase, #p <
0.05 reduction) was determined using two-way ANOVA followed by post-hoc Bonferroni test. b Results of reporter gene assays showing changes in
Brn-3b promoter activity in cells that co-express constitutively active CnA either alone (CnA) or with the calcineurin inhibitor, CsA (CnA+ CsA), when
compared with CsA alone (1 µM). Promoter activity are also shown under different combinations of treatment i.e. CnA+ AngII, in the absence or
presence of different inhibitors, CsA and/or PD. The data represent the results of independent experiments (n= 6) and are expressed relative to levels
found in untreated control cells (set at 100). Signiﬁcant increases: **p < 0.01, *p < 0.05; ##signiﬁcant reduction following treatment with inhibitor CsA
(1 µM). c Western blot analysis showing Brn-3b expression in H9c2 cells either untreated (Con) or pretreated as indicated with either MAPK/ERK
inhibitor, SB203580 (SB:5 µM) or calcineurin inhibitor, ascomycin (Asc:1uM) for 30 min prior to AngII treatment (10 µg/ml). d Schematic diagram
showing the location of multiple NFAT binding sites on 6 kb region of the rat Brn-3b promoter following bioinformatic analysis using MatInspector™.
+1 indicates the approximate position of the putative start site. PCR primers were designed to ﬂank putative NFAT binding sites in the Brn-3b
promoter. Horizontal arrows indicate positions of forward (F) and reverse (R) primers which were well conserved between rat and human sequence
and which were used for ChIP assay. e PCR products obtained using the indicated primers set ﬂanking NFAT sites, indicated by arrows (above) input
DNA (chromatin DNA prior to immunoprecipitation) or ChIP DNA obtained after immunoprecipitation with NFAT Abs in either untreated or AngII-
treated H9c2 cells. This was compared with negative ChIP DNA control (incubated with second Ab) or PCR negative (without DNA). The marker lane
(M) shows the DNA ladder used to identify fragment size in the gel. f (i) Representative western blot showing Brn-3b(s) protein in hearts isolated from
4-week transgenic (TG) mice with cardiac-speciﬁc CnA overexpression or non-transgenic (non TG) littermates. The invariant protein GAPDH was used
to control for protein loading. (ii) Quantiﬁcation of Brn-3b(s) proteins in WT or CnA-TG mouse hearts, following normalisation with control GAPDH
protein. **p < 0.01
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Loss of Brn-3b causes altered heart function at baseline
To determine how loss of Brn-3b affected cardiac
function at baseline, PV loop measurements were
undertaken on available male Brn-3b KO mutants (n= 6;
11 months) and age-matched WT controls. Figure 6a
shows a summary of key changes observed in Brn-3b KO
hearts. Lower ESPVR and a trend of reduced arterial
elastance, (Ea), in mutant hearts may indicate reduced
contractility and this was associated with lower ejection
fraction (EF); pressure–volume area (PVA); reduced
stroke work (SW) and pre-load recruitable stroke work
(PRSW), which suggests reduced efﬁciency. Similarly,
Fig. 5 Brn-3b target genes are regulated following AngII treatment. a (i) Representative western blots showing changes in different proteins
including Brn-3b(s) and hypertrophic marker β-MHC as well as known Brn-3b target genes GLUT4 and cyclin D1, in hearts taken from wild-type mice
treated with AngII and compared with control hearts taken from age-matched control mice infused with saline (Sal). The approximate molecular
weight (kD) of each protein is indicated. β-tubulin or GADPH are included to show variation in protein loading between samples. (ii) Graphical
representation showing changes in Brn-3b and β-MHC proteins in AngII-treated WT hearts compared with saline controls (n ≥ 7). *p < 0.05, evaluated
with students’ t test. (iii) Representative blots showing Bax and p53 proteins quantiﬁed in cellular extracts (as above). β-tubulin indicates variation in
proteins loading from different samples. b Representative western blot showing changes in Brn-3b(s), GLUT4 and cyclin D1 protein levels in NRVM
following treatment with AngII, compared with untreated controls while β-tubulin indicates variation in proteins loading from different samples. c
Representative western blots showing Brn-3b, βMHC and Brn-3b target genes, GLUT4 and cyclin D1 in H9c2 cells, at different times after AngII
treatment. (ii) Western blots showing increased pro-apoptotic Bax protein at later stages after AngII treatment
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mutant hearts showed that changes in dV/dtMax, an
indicator of cardiac contractility, was associated with
increased end systolic volume (ESV) (KO= 28ml ± 16)
when compared with WT controls (WT-13.9 ± 6.5), albeit
not reaching signiﬁcance due to large variability. Never-
theless, such ﬁndings may indicate that mutant hearts
cannot empty effectively, resulting in higher ESV. Similar
adverse changes in function of Brn-3b KO hearts were
also demonstrated by echocardiography, which showed
reduced fractional area change (FAC); fractional short-
ening (FS) and increased ESV, compared with WT control
hearts. Therefore, echocardiography was used for sub-
sequent longitudinal analyses of heart function, in AngII-
treated and control mice.
Fig. 6 Baseline differences in Brn-3b KO heart function. a Summary of results from pressure–volume measurements in mouse hearts collected
using the Scisense ADVantageTM Admittance PV loop system, analysed with PowerLab software and statistical signiﬁcance determined using
students t test in Excel and Prism. Data represents mean and standard error (±) from six mice within each group (11 months old). *p ≤ 0.05. ESPVR=
end systolic pressure–volume relationship; Ea arterial elastance; PRSW preload recruitable stroke work; PVA pressure–volume area; dV/dtMax maximum
conductance velocity; Ves end systolic volume; HW heart weight; HW:BW ratio heart weight:body weight ratio. b Echocardiography data showing
parameters that are altered in Brn-3b KO mouse hearts when compared with age-matched WT control hearts. Data represent mean and standard
error of multiple hearts (n ≥ 5)
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Fig. 7 (See legend on next page.)
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Attenuated hypertrophic responses in Brn-3b KO mutants
following AngII treatment
To study how loss of Brn-3b affected hypertrophic
responses in the heart, male Brn-3b KO mice (~2 months
old) and age-matched WT littermates were administered
with AngII or saline (via mini osmotic pumps; up to
4 weeks). Figure 7a(i, ii) shows that AngII treatment
resulted in the expected hypertrophic responses in WT
hearts, i.e. increased LV mass and HW:BW ratio, when
compared with saline controls. This was conﬁrmed by
analysing cardiomyocyte area in AngII-treated or control
heart sections, stained to delineate cell membrane e.g.
WGA (Fig. 7a(iii)) or histological stains (H+ E or Masson’s
trichrome) (Fig. 7a(iv)). Quantiﬁcation of area change, using
image J, showed signiﬁcant increases in cardiomyocyte area
in AngII-treated WT hearts, when compared with saline
control WT hearts (Fig. 7a(v)), whereas no signiﬁcant dif-
ferences were observed in AngII-treated Brn-3b KO hearts
either in LV mass (Fig. 6a(i)), HW:BW ratio (Fig. 7a(ii)) or
cardiomyocyte area (Fig. 7a(iii–v)).
At the molecular level, increased Brn-3b expression in
AngII was associated with an expected induction of
βMHC in WT hearts, either at mRNA or protein levels
(Fig. 7b(ii), c(ii)) but β-MHC mRNA and protein were
unchanged in AngII-treated Brn-3b KO hearts (Fig. 7b(ii),
c(i)). The Brn-3b target gene, GLUT4, was also reduced in
AngII-treated Brn-3b KO hearts, when compared with
WT controls (Fig. 6c(ii)) suggesting that the loss of such
Brn-3b target genes may contribute to altered responses
in the mutant hearts.
Reduced cardiac function in AngII-treated Brn-3b KO
hearts correlates with increased ﬁbrosis and adverse
remodelling
Echocardiography analysis of AngII treated and control
hearts also revealed subtle but clear differences in cardiac
function of Brn-3b KO when compared with WT hearts,
either at baseline or in response to AngII (Fig. 8a, b).
Thus, Brn-3b KO mutants displayed higher high ESV at
baseline [a(i)] and reduced FAC, which were associated
with increased cardiac output (CO) (b). Moreover, AngII
treatment caused signiﬁcant reduction in CO and EF but
sustained high ESV in Brn-3b KO mice, which may
indicate failure of the mutant heart to cope with stress.
Masson’s Trichrome staining of experimental hearts
identiﬁed structural changes in AngII-treated Brn-3b KO
(Fig. 8c) with evidence for increased extracellular matrix
deposition and ﬁbrosis (blue), particularly in the left
ventricle and around blood vessels, when compared with
AngII-treated WT hearts. Quantiﬁcation of the ﬁbrotic
areas showed signiﬁcantly more ﬁbrosis in Brn-3b KO
hearts when compared with WT controls (Fig. 8c(iii)).
Analysis for expression of ﬁbrotic marker, phospho-
SMAD, showed signiﬁcantly increased staining in AngII-
treated Brn-3b KO hearts (lower panel, Fig. 8d) when
compared with appropriate WT hearts (top panel).
TUNEL staining to analyse for cell death also showed
increased staining in AngII-treated Brn-3b KO when
compared with AngII-treated WT hearts (Fig. 7e). These
ﬁndings suggest that adverse remodelling in Brn-3b KO
hearts is associated with increased cell death, which may
contribute to dilatation and reduced contractile function
seen by echocardiography.
Discussion
Terminally differentiated cardiomyocytes in adult hearts
cannot proliferate readily in response to chronic cardiac
stressors so adapt by undergoing hypertrophic growth to
maintain cardiac output and function. Characteristic
adaptive changes such as sarcomeric reorganisation and
metabolic switching, arise because of extensive repro-
gramming of gene expression2,53, which includes re-
expression of foetal genes (e.g. β−MHC and ANP), cell
cycle genes (e.g. cyclin D1/CDK4) and oncogenes (e.g. c-
fos or c-myc)18 or increased expression of GLUT4 glucose
transporter20,54. In contrast, sustained stress which induce
pro-apoptotic genes e.g. p53 and Bax, can contribute to
irreversible cardiomyocyte death, adverse remodelling and
subsequent progression to heart failure25. Yet, master
regulators that control the transition between early
adaptive responses and pathological events are not fully
understood1,53. Previous studies have shown that the Brn-
(see ﬁgure on previous page)
Fig. 7 Attenuated hypertrophic responses to AngII in Brn-3b KO hearts. Echocardiography data showing changes in (i) LV mass or (ii) HW:BW
ratio, in hearts from male Brn-3b KO (KO) mice and age-matched, WT control mice following AngII or saline infusion for 4 weeks. Groups of 6–8 mice
were used and data represent the mean and standard error.**p < 0.01 using either students t test or two-way ANOVA and post-hoc Bonferroni
analyses. (iii) Representative images showing changes in cardiomyocyte size in hearts taken from WT or Brn-3b KO mice, infused with either saline
(Sal) or AngII and stained with wheat germ agglutinin (WGA) or (iv) histochemical staining, e.g Masson’s trichrome. Images shown at ×20
magniﬁcation. Dotted lines show representative cell surface area used for analysing differences in cardiomyocyte size in wild-type or Brn-3b KO
hearts following AngII-treated and compared with appropriate saline controls (v) The mean ± SEM of cell surface area measurements taken from
multiple hearts (n ≥ 3 independent hearts) with >30 cells analysed from each heart section. b Data from qRT-PCR to analyse changes in (i) Brn-3b or
(ii) β−MHC mRNA in hearts taken from AngII or saline-treated WT male mice or Brn-3b KO mutants. c Representative western blots showing changes
in protein expression, as indicated, in hearts taken from WT and Brn-3b KO mutants, treated with AngII or saline controls (Sal). β-tubulin blots show
difference in total protein between samples
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3b TF is re-expressed in injured cardiomyocytes and can
alter cell fate40,43 and in this study we show that Brn-3b is
induced in response to hypertrophic stress and may have
potentially important roles in controlling hypertrophic
responses in the heart.
Brn-3b mRNA and protein are induced by AngII
treatment in WT mouse hearts that undergo character-
istic hypertrophic changes including increased LV mass
and HW:BW ratio and re-expression of hypertrophic
genes e.g. βMHC, ANP55. Since AngII treatment induces
Fig. 8 Reduced cardiac function in male Brn-3b KO hearts following AngII treatment. a. Echocardiography data showing changes in (i) end
systolic volumes or (ii) fractional area change in Brn-3b KO hearts compared with WT control either in control saline (Sal) hearts or hearts infused with
AngII (AII) for 4 weeks. Signiﬁcant differences between groups are indicated by (**), as determined either using Students t test or two-way ANOVA
and Bonferroni post-hoc test. b Changes in cardiac output (i) or ejection fraction (ii) in untreated control (Sal) WT or Brn-3b KO mice or treated with
AngII for up to 4 weeks. Data represents the mean and standard error from 6–8 mice per group. Statistical signiﬁcance between groups was
determined using Students t test or two-way ANOVA and Bonferroni post-hoc test (*<0.05; **<0.01). c Representative images showing Masson’s
trichrome staining of hearts sections prepared from (i) Brn-3b KO mice treated with AngII, or (ii) WT control mice treated with AngII. Images were
captured using Hammamatsu Nanozoomer imaging system and shown at ×1.5–40 magniﬁcation. Red/Pink staining represent cytoplasm staining in
muscle cells, dark purple/black indicates cell nuclei and blue staining indicates deposition of extracellular matrix proteins e.g. collagen. (iii) Graph
representing differences in the areas with signs of ﬁbrosis (increased ECM deposition) in WT or Brn-3b heart following AngII treatment. Areas of
ﬁbrosis were measured using image J in ≥5 independent heart sections, shown as ± SEM and signiﬁcance determined using students t test (***p <
0.001). d Representative images showing anti-phospho-SMAD 3 antibody DAB immunostaining in sections of hearts taken from AngII-treated mice as
indicated [WT mice (top panel) or Brn-3b KO mice (lower panel)]. Positive cells are stained brown in images shown either at lower magniﬁcation
(×2.5) to highlight the extent of increased SMAD protein expression in AngII-treated Brn-3b KO hearts or at higher magniﬁcation (×10) displays the
intensity of staining. e Representative TUNEL staining in heart sections taken from AngII-treated WT mice (top panel) or Brn-3b KO mice (lower panel).
TUNEL positive cells appear brown in the images (shown at ×40 magniﬁcation)
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Brn-3b mRNA and protein in isolated NRVM that
undergo hypertrophy48, we conclude that Brn-3b induc-
tion in cardiomyocytes will be important for hypertrophic
responses in the heart. Similarly, AngII stimulates Brn-3b
mRNA and protein in hypertrophic H9c2 cells expressing
β-MHC and displaying characteristic sarcomeric remo-
delling. Based on these ﬁndings and data from previous
studies40, we determined that the rat heart-derived H9c2
cell line provides a useful adjunct for studying the effects
of Brn-3b in cardiomyocytes40,42.
At the protein level, AngII treatment causes preferential
increase in the Brn-3b(s) isoform and while the roles for
the distinct Brn-3b isoforms are still unclear, high levels of
Brn-3b(s) protein is strongly associated with increased
proliferative and oncogenic potential cancer cells34,35.
This is interesting because re-expression of foetal onco-
genes is a characteristic feature of cardiac hypertrophy
and may represent an adaptive response to chronic
stress18,56. However, whereas oncogenes such as c-fos and
c-myc display immediate-early (IE) expression proﬁles in
hypertrophic hearts (30–60 min, respectively)18,56, Brn-3b
expression is sustained in for up to 24 h and may therefore
have as yet unknown roles in the stressed heart.
Importantly, Brn-3b activation in hypertrophic cardio-
myocytes occurs via different, well-characterised hyper-
trophic signalling pathways including p42/44 MAPK and
CnA, suggesting that it may be a central mediator of
hypertrophic responses in cardiomyocytes. The effects of
AngII on the Brn-3b promoter are mediated via the p42/44
MAPK pathway and are blocked by the MEK1/2 inhibitor,
PD98059 but not by p38 MAPK inhibitor (SB203580)56–59.
This is consistent with previous studies showing that p42/
44 MAPK pathway is important for activation of the Brn-3b
promoter in human breast cancer cells47.
Brn-3b activation by CnA, is also highly relevant
because of the central role of this pathway in driving
hypertrophic responses in the heart11. Furthermore,
higher endogenous Brn-3b levels in hearts from cardiac-
speciﬁc CnA transgenic mice13 indicate that this TF is a
downstream target of CnA. This is further strengthened
by the presence of multiple NFAT binding sites in the
proximal Brn-3b promoter and ChIP assay data showing
that NFAT protein is, indeed, bound to the Brn-3b pro-
moter, in vivo13,14.
Interestingly, there is an overlap between AngII and
CnA pathways in regulating Brn-3b expression because
AngII treatment increases NFAT binding to the promoter
whereas the CnA inhibitor, ascomicin, blocks AngII
induction of Brn-3b. Crosstalk between MAPK/ERK and
CnA pathways have been reported previously since AngII
can directly activate the CnA pathway49, whereas ERK1/2
phosphorylation of an N-terminal serine residue in NFAT
can enhance transcriptional activity on its target
genes11,14. CnA may also be activated indirectly by MEK5/
ERK5 (BMK)60, which phosphorylates and inhibits the
negative regulator, MCIP1 following AngII stimulation61.
This data suggests that canonical hypertrophic mediators
such as AngII and CnA converge to activate Brn-3b in
cardiomyocytes so this master regulator is likely to play a
central role in hypertrophic responses in stressed hearts.
As a TF, Brn-3b(s) regulates multiple target genes and
thereby drive complex cellular effects. Here we show that
known Brn-3b target genes, cyclin D134, GLUT430 and
Bax40,41, are increased by AngII in intact hearts, isolated
NRVM cultures or H9c2 cells. Time-course studies
identify differential expression patterns of Brn-3b target
genes following AngII treatment with maximal expression
of cyclin D1 and GLUT4 seen at earlier time points when
pro-apoptotic Bax expression is low but are reduced by
24 h, when Bax is maximally induced. Although different
Brn-3b target genes are implicated in hypertrophic
responses, each is associated with distinct cellular effects.
For example, cyclin D1 KO mice display attenuated
hypertrophy, whereas transgenic mice over-expressing
cyclin D1 develop enlarged hearts16,17. Similarly, GLUT4,
is increased in hypertrophic hearts30 and may contribute
to metabolic switching, from fatty acid to glucose meta-
bolism in stressed hearts54. In contrast, induction of Bax
and p53 are linked to cardiomyocyte apoptosis in failing
hearts25,62,63. We found low p53 levels in normal hearts
but increased expression in AngII-treated hypertrophic
hearts. However, cell culture models, NRVM and H9C2,
express higher basal p53 levels, which may reﬂect apop-
tosis associated with increased cell turnover. Although
p53 can stimulate Bax, maximal activation in NRVM
requires co-expression of Brn-3b and p53 since siRNA to
reduce Brn-3b can block Bax induction despite sustained
p53 expression. Therefore, Brn-3b may regulate distinct
target genes in hypertrophic cardiomyocytes at early
stages when p53 expression is low but, at later stages,
when p53 is increased, it may cooperate with p53 to drive
apoptotic effects associated with pathological changes.
Analyses of heart function in male Brn-3b KO mice
have also identiﬁed key baseline differences between
mutant and WT control hearts, which conﬁrms essential
functions for this TF in controlling cardiac function. PV
loop analyses carried out on 11-month-old male mice
show contractile dysfunction in Brn-3b KO mutants
which is reﬂected in reduced ESPVR, Ea, EF and reduced
capacity for work, i.e. reduced SW, PRSW and PVA.
Increased dV/dtMax and increased ESV suggests that
mutant hearts are less effective at emptying at end systole,
when compared with age match WT controls. Brn-3b KO
mutants also show clear trends towards lower HW and
HW/BW ratio but high variability meant this did not
reach statistical signiﬁcance so will have to be conﬁrmed
in larger studies. Contractile dysfunctions in male Brn-3b
KO hearts are also detected using echocardiography e.g.
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reduced FAC and FS and increased ESV. Since this
technique offers advantages for undertaking longitudinal
studies over PV loop studies, which is normally done as
terminal procedure, then echocardiography was used to
analyse heart function in many later studies.
Importantly, hearts from Brn-3b KO mice display
blunted response to AngII treatment, which induces the
expected hypertrophic changes in WT male hearts. Fur-
thermore, adverse functional and contractile changes in
mutant hearts at baseline, are worsened following AngII
treatment with poor contractile function linked to
reduced CO and EF and increased ESV. There is also
evidence for extensive ﬁbrosis and remodelling in AngII-
treated Brn-3b KO hearts, particularly in left ventricle and
around blood vessels of AngII-treated male which corre-
lates with increased phospho-SMAD-3, a marker of
pathological remodelling in stressed hearts. As a down-
stream effector of TGF beta pathway, phospho-SMAD 3,
is implicated in pathological responses to chronic stress in
murine hearts64, so increased phospho-SMAD 3 indicates
maladaptive responses in AngII-treated Brn-3b KO
hearts. Similarly, increased cardiomyocyte death, detected
by TUNEL staining in AngII-treated Brn-3b KO hearts,
suggest failure of mutant hearts to adapt to stress, which
may result in progression to heart failure.
Further analysis of mutant hearts and WT controls for
changes in known Brn-3b target genes associated with
hypertrophic responses suggest complex roles for this
regulator in controlling cardiomyocytes fate. For example,
although Brn-3b can cooperate with p53 to induce pro-
apoptotic Bax, AngII-treated Brn-3b KO hearts show
evidence for increased cardiomyocyte death, thus impli-
cating Brn-3b in other early responses required for
adaptation and survival of these cells. Furthermore,
GLUT4, which is an insulin-responsive transporter asso-
ciated with metabolic switching from fatty acid to glucose
metabolism, is signiﬁcantly reduced in AngII-treated Brn-
3b KO hearts, so may represent an important Brn-3b
target gene required for in mediating hypertrophic
responses in the heart. However, other as yet unknown,
cardiac-speciﬁc target genes regulated by Brn-3b, may
also play important roles in this process51,65. Thus, Brn-3b
may represent a novel regulator that is required to control
adaptive hypertrophic responses in male heart, in
response to stress.
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